Anti-HER2 monoclonal antibodies intensify the susceptibility of human gastric cancer cells to etoposide by promoting apoptosis, but not autophagy.

<h4>Background</h4>Gastric cancer (GC) is a multifactorial disease with high mortality. Anti-HER2 therapy is a promising strategy in GC treatment and trastuzumab was approved by FDA (Food and Drug Administration) as the first and the second line of treatment of the disease.<h4>Purp...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Agnieszka Gornowicz, Wojciech Szymanowski, Robert Czarnomysy, Krzysztof Bielawski, Anna Bielawska
Format: article
Langue:EN
Publié: Public Library of Science (PLoS) 2021
Sujets:
R
Q
Accès en ligne:https://doaj.org/article/e3fb1a28599f41c8bab125cc710e68f0
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!